Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Half of pharmacists 'struggling' to meet revised MUR targets

Fifty-three per cent of C+D readers say they have difficulty increasing the proportion of reviews they deliver to patients from the four target groups from 50 to 70 per cent

EXCLUSIVE

More than half of pharmacists are struggling to hit their revised MUR targets, a C+D survey has revealed.

As set out in last October’s funding settlement, the proportion of a pharmacy’s 400 annual MURs that must be delivered to patients from four target groups officially increased from 50 to 70 per cent on April 1.

But 53 per cent of 175 respondents to a C+D poll, which ran from March 23 to April 7, said they struggled to locate enough individuals from the four groups: those on high-risk medicines, with respiratory conditions, recently discharged from hospital, or at risk of or diagnosed with cardiovascular disease.

The remaining 47 per cent said they found it “easy” to find enough patients in these groups.

PSNC service development committee chair Gary Warner defended the quota increase, arguing that focusing on specific patient groups allowed the sector to help patients who would benefit most from an intervention, he told C+D.

“PSNC supported the changes to MUR requirements following [an] analysis [that] confirmed the feasibility of the changes, and we agreed a phased introduction to further ease the transition for contractors,” he said.

“If all pharmacies in England were to offer 400 MURs, that would need around 3.25 million patients in target groups. Data suggests there are more than 4 million people with asthma and COPD, 7 million with hypertension [and] over 2.5 million with diabetes,” he said.

Amish Patel, owner of Hodgson Pharmacy in Kent, said he was “a bit surprised” by the figures. “It’s a new change, and everyone struggles with change to begin with. People were struggling to hit 400 MURs; now they’re hitting 400 and the targets are changing.

“I guess less busy pharmacies might struggle, but if you’ve got a high dispensing level it shouldn’t be hard to find 400 people out of the thousands coming through the door,” he told C+D.

Numark director of pharmacy services Mimi Lau said targeted MURs “require planning, and that is probably the reason why some pharmacists are struggling with them”.

Day Lewis managing director Kirit Patel said his pharmacists were “not struggling” to reach their MUR targets. “We average 382 across all our stores. It’s only two a day, and you can’t tell me two a day is impossible,” he told C+D.

PSNC said last year that the addition of the cardiovascular group – which could be targeted for an MUR from last December – would help pharmacies reach their 70 per cent quota.

MUR tips – how to hit your targets

“To achieve 70 per cent, pharmacists need to ensure these patients are flagged up to them, either by the pharmacy staff on receipt of a prescription or by the PMR system as part of the labelling process.”
Mimi Lau, director of pharmacy services, Numark
 
“It’s to do with support. You need to have the right skill-mix and training [or] there’s too much pressure on the pharmacist. We recruit people who are able to dispense, freeing up the pharmacists’ time.”
Kirit Patel, managing director, Day Lewis



How do you target MURs to the correct patient groups?

We want to hear your views, but please express them in the spirit of a constructive, professional debate. For more information about what this means, please click here to see our community principles and information

Related Content

Topics


            
Pharmacy Technician
 Falkland Islands (FK)
£25k - £28k plus Flights, Gratuity and Relocation Grant

Apply Now
UsernamePublicRestriction

Register

CD007362

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel